Min Daliu, Lin Feng, Shen Zan, Zheng Shuier, Tan Lina, Yu Wenxi, Yao Yang
Department of Medical Oncology, The Affiliated 6th People's Hospital of Shanghai Jiaotong University, Shanghai, China.
Asia Pac J Clin Oncol. 2013 Mar;9(1):71-9. doi: 10.1111/j.1743-7563.2012.01560.x. Epub 2012 Jul 23.
To investigate prognostic factors for long-term outcomes in Chinese patients with high-grade osteosarcoma of the extremities or trunk treated by multidisciplinary combined therapy.
In total, 333 consecutive patients with non-metastatic or primary metastatic high-grade osteosarcoma of the extremities or trunk were retrospectively reviewed to analyze the correlation between survival and sex, age, site, histological type, clinical stage, alkaline phosphatase (ALP) level, preoperative chemotherapy or not, response to preoperative chemotherapy, postoperative chemotherapy cycles and manner of surgery. The combined therapy included preoperative and postoperative chemotherapy as well as limb salvage surgery or amputation.
The median survival time was 52 months for all 333 patients. Univariate analysis revealed that sex, ALP level, preoperative chemotherapy and cycle numbers of postoperative chemotherapy may influence the prognosis of high-grade osteosarcoma of the extremities or trunk. Multivariate analysis revealed that the female, a normal ALP level, preoperative chemotherapy with good response and ≥4 cycles of postoperative chemotherapy correlated with a better outcome.
Preoperative chemotherapy is important in high-grade osteosarcoma treatment and a good response to it is an important marker of prognosis. It should be given with ≥ cycles of postoperative chemotherapy after surgery.
探讨多学科联合治疗的中国四肢或躯干高级别骨肉瘤患者长期预后的相关因素。
回顾性分析333例连续性四肢或躯干非转移性或原发性转移性高级别骨肉瘤患者,分析生存与性别、年龄、部位、组织学类型、临床分期、碱性磷酸酶(ALP)水平、是否接受术前化疗、对术前化疗的反应、术后化疗周期及手术方式之间的相关性。联合治疗包括术前和术后化疗以及保肢手术或截肢。
333例患者的中位生存时间为52个月。单因素分析显示,性别、ALP水平、术前化疗及术后化疗周期数可能影响四肢或躯干高级别骨肉瘤的预后。多因素分析显示,女性、ALP水平正常、术前化疗反应良好及术后化疗≥4周期与较好的预后相关。
术前化疗在高级别骨肉瘤治疗中很重要,对其反应良好是预后的重要指标。术后应给予≥化疗周期的术后化疗。